research Disease severity scoring systems in dermatology
Scoring systems help doctors assess and treat skin diseases effectively.
Search
for
Sort by
Research
30-60 / 1000+ results 
research PSS33 REAL-LIFE DOSING OF BIOLOGICS IN PLAQUE PSORIASIS—A GERMAN SURVEY
Real-life dosing of biologics for plaque psoriasis often deviates from recommended guidelines, especially for high-need patients.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
research Estimation of Claudin 3 in the Sreum of Alopecia Areata Patients and Its Association with Disease Severity
Higher Claudin 3 levels in the blood are linked to more severe alopecia areata.
research Cellular retinol‐binding protein‐1 expression increases with increasing clinical severity of alopecia areata
Higher CRBP1 levels are linked to more severe alopecia areata.
research Ixekizumab shows efficacy and safety in patients who failed biweekly etanercept therapy: Analysis From UNCOVER-2, a phase 3 randomized clinical trial in psoriasis
Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.
research Assessing the burden of dermatological diseases on work life from a gender perspective
Dermatological diseases affect women's work performance more than men's.
research Phosphodiesterase (PDE) Inhibitors for the Treatment of Inflammatory Skin Conditions
PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.
research Longitudinal clinical course, treatment outcomes, and relapse patterns in alopecia areata: a prospective cohort study
Baseline severity and relapse history affect alopecia areata treatment and recurrence.
research การศึกษาแบบสุ่มแบ่งครึ่งข้างเพื่อเปรียบเทียบประสิทธิภาพการฉีดโบทูลินัมทอกซินชนิดเอกับ 0.9% โซเดียมคลอไรด์ในผื่นสะเก็ดเงินบนศีรษะ
Botulinum toxin type A significantly reduces scalp psoriasis severity compared to placebo.
research Psoriasis Course in Patients with Alopecia Areata Undergoing Baricitinib Therapy
Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.
research Psoriasis Course in Patients with Alopecia Areata Undergoing Baricitinib Therapy
Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.
research Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis
Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
research Serum prolactin levels in dermatological diseases: A case–control study
People with certain skin diseases have higher levels of the hormone prolactin in their blood.
research CGF therapy: bridging androgenetic alopecia observations to psoriasis treatment via IL-17 pathway
CGF therapy may effectively treat psoriasis by reducing inflammation.
research Incidence of serious infectious events with methotrexate treatment: Metaanalysis of randomized controlled trials
Methotrexate treatment for rheumatoid arthritis has a serious infection rate of about two per 100 patient-years.
research Quality of life in patients with alopecia areata: a hospital‐based cross‐sectional study
Alopecia areata significantly lowers quality of life, especially in personal and social areas, and more so if the patient is also depressed.
research Tofacitinib in the Recalcitrant Cases of Alopecia Areata: A Pilot Study
Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.
research Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
research Alopecia areata and vitamin D: Is there any association?
People with alopecia areata often have lower vitamin D levels than healthy people.
research Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
STS01 1% effectively promotes hair regrowth with minimal side effects.
research Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
research Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
Baricitinib is effective and safe for treating severe alopecia areata.
research A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
Apremilast was not effective in treating moderate-to-severe alopecia areata.
research Mild-to-moderate COVID-19 is not associated with worsening of alopecia areata: A retrospective analysis of 32 patients
COVID-19 doesn't make alopecia areata worse.
research Prospective, Open-Label, Multi-Centre, Randomized Study to Compare the Effectiveness, Safety, and Tolerability of Lulican™ Shampoo Versus Ketoconazole Shampoo in Indian Adult Patients With Mild to Moderate Scalp Seborrheic Dermatitis (LEAD Study)
Lulican™ shampoo is more effective and better tolerated than Ketoconazole for treating scalp seborrheic dermatitis.
research Journal of Population Therapeutics and Clinical Pharmacology
Baricitinib is more effective than methotrexate for severe alopecia areata.
research Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Efficacy of Oral Apremilast in The Treatment of Alopecia Areata, at The Tertiary Care Hospital, Karachi
Oral Apremilast effectively treats alopecia areata in most patients.